Praxis Precision Medicines halted its registrational-phase EMBOLD trial of relutrigine in developmental and epileptic encephalopathies after an interim analysis showed strong efficacy. The early stop was for positive efficacy, and the company said it will use the data to advance regulatory discussions with the FDA. The readout prompted an immediate market reaction, with Praxis shares rising sharply on the interim findings. Reporting referenced trial design details and company disclosures; the trial’s early closure accelerates the path toward potential approval filings and highlights sodium channel modulation as a clinical strategy in rare genetic epilepsy syndromes. Clinical and regulatory next steps include filing discussions and confirmatory analyses; company statements and BioCentury coverage provide the primary public record.